Cidara Therapeutics Files 8-K

Cidara Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyCidara Therapeutics, Inc.
Form Type8-K
Filed DateJun 24, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 8-k, sec-filing, other-events

Related Tickers: CDTX

TL;DR

Cidara Therapeutics (CDTX) filed an 8-K on 6/24/25 for 'Other Events' - need to check full filing for details.

AI Summary

On June 24, 2025, Cidara Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transactions or material events are detailed in the provided excerpt.

Why It Matters

This filing signals that Cidara Therapeutics has reported a material event to the SEC, requiring public disclosure. Investors should review the full filing for details on the nature of these 'Other Events'.

Risk Assessment

Risk Level: medium — The risk level is medium because an 8-K filing indicates a material event has occurred, but the excerpt does not specify the nature or impact of this event, leaving room for uncertainty.

Key Players & Entities

  • Cidara Therapeutics, Inc. (company) — Registrant
  • June 24, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 001-36912 (identifier) — Commission File Number
  • 46-1537286 (identifier) — I.R.S. Employer Identification Number
  • 6310 Nancy Ridge Drive, Suite 101 (address) — Principal Executive Offices
  • San Diego, California 92121 (address) — Principal Executive Offices
  • 858-752-6170 (phone_number) — Principal Executive Offices Telephone Number

FAQ

What specific 'Other Events' are being reported by Cidara Therapeutics in this 8-K filing?

The provided excerpt of the 8-K filing does not specify the nature of the 'Other Events'. A review of the full document is required to ascertain the details.

When was this 8-K filing submitted to the SEC?

The filing was submitted on June 24, 2025.

What is Cidara Therapeutics, Inc.'s principal executive office address?

Cidara Therapeutics, Inc.'s principal executive offices are located at 6310 Nancy Ridge Drive, Suite 101, San Diego, California 92121.

What is Cidara Therapeutics, Inc.'s Commission File Number?

Cidara Therapeutics, Inc.'s Commission File Number is 001-36912.

What is the Standard Industrial Classification (SIC) code for Cidara Therapeutics, Inc.?

The SIC code for Cidara Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 24, 2025 regarding Cidara Therapeutics, Inc..

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.